Diabetes Metab J.  2016 Aug;40(4):334-335. 10.4093/dmj.2016.40.4.334.

Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)

• Kim JH

• KMID: 2368521
• DOI: http://doi.org/10.4093/dmj.2016.40.4.334

Abstract

No abstract available.

MeSH Terms

Diabetes Mellitus, Type 2*
Humans

Reference

1. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001; 161:1989–1996.

2. Verne GN, Sninsky CA. Diabetes and the gastrointestinal tract. Gastroenterol Clin North Am. 1998; 27:861–874. vi–vii.

3. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement: a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006; 3:138–148.

4. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008; 48:379–384.

5. McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, Deren J, Ippoliti A, Olsen HW, Falchuk K, Hersh T. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983; 6:463–467.

6. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004; 351:1089–1096.

7. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut. 2010; 59:1716–1726.

8. Park S, Park SY, Kim YJ, Hong SM, Chon S, Oh S, Woo JT, Kim SW, Kim YS, Rhee SY. Effects of rebamipide on gastrointestinal symptoms in patients with type 2 diabetes mellitus. Diabetes Metab J. 2016; 40:240–247.

9. American Diabetes Association. 7. Approaches to Glycemic Treatment. Diabetes Care. 2016; 39:Suppl 1. S52–S59.